A novel biosensor for quantitative monitoring of on-target activity of paclitaxel
- 8 December 2014
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 7 (3) , 1127-1135
Abstract
This study describes a system for quantifying paclitaxel activity using the C-terminus of α-tubulin as a biomarker. Following stabilization of microtubules with paclitaxel, a specific detyrosination reaction occurs at the C-terminus of α-tubulin which could be used to assess efficacy. A fluorescence resonance energy transfer (FRET) based biosensor was synthesized comprising a short peptide that corresponded to the C-terminus of α-tubulin, a fluorophore (Abz), and a quencher (Dnp). The fluorophore added to the end of the peptide can be released upon enzymatic detyrosination. In addition, a single fluorophore-tagged peptide was also conjugated to mesoporous silica nanoparticles to examine the feasibility of combining the drug with the peptide biomarker. As a proof of concept, we found that the degree of peptide cleavage, and therefore enzymatic activity, was directly correlated with exogenous bovine carboxypeptidase (CPA) an enzyme that mimics endogenous detyrosination. In addition, we show that cell lysates obtained from paclitaxel-treated cancer cells competed with exogenous CPA for biosensor cleavage in a paclitaxel dose-dependent manner. Our work provides strong evidence for the feasibility of combining paclitaxel with a novel biosensor in a multi-load nanoparticle.Keywords
This publication has 46 references indexed in Scilit:
- Modulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to PaclitaxelCancer Research, 2011
- Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of PaclitaxelInternational Journal of Molecular Sciences, 2011
- Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian CellsSmall, 2010
- Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid TumorsJapanese Journal of Clinical Oncology, 2010
- Recent advances in peptide probe-based biosensors for detection of infectious agentsJournal of Microbiological Methods, 2009
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel andnab-PaclitaxelClinical Cancer Research, 2008
- The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to PaclitaxelCancer Cell, 2007
- Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer CellsNanoBiotechnology, 2007
- Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer DrugsClinical Pharmacokinetics, 1989